Cellgram-AKI

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCellgram-AKI
Drug Alias Nameallogeneic mesenchymal stem cell therapy (Pharmicell)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cells modulators
TargetsUpdating
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesFcb-Pharmicell
China Registration ClassN/A

Develop Information

Active CompaniesFcb-Pharmicell
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Renal InsufficiencyRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A